News

Zybrestat selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. Falcon is a randomized, controlled Phase 2 study investigating

Veeva CRM will help HGS with all specialty care sales reps and medical science liaisons in Germany, Spain and France. According to HGS, Veeva’s pharmaceutical industry expertise and

Under the supply agreement, Z-Medica will supply QuikClot hemostatic products used in the interventional medical field to Premier member hospitals. This agreement will also provide access for specially

The products include Defend Cold and Cough, Defend Cold and Cough Night, Defend Sinus, for adults and Baby Cough Syrup. The natural formulations are non-drowsy and do not

Aslan has gained rights to develop and market BMS-777607 in Australia,China, Korea, Taiwan and other selected Asian countries while Bristol-Myers Squibb retains rights at the rest of the

After filing IND (Investigational New Drug) with the FDA and the completion of the phase IIb study, the Company licensed the global rights of Lupuzor to Cephalon. Following

Lixisenatide, discovered by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for Type-2 diabetes . Sanofi is set to complete Phase III development of

The double-blind, multicentre, placebo-controlled, randomised CUV030 study was designed to assess the safety and efficacy of subcutaneous bioresorbable afamelanotide implants in reducing phototoxic skin reactions in erythropoietic protoporphyria

Mibefradil, used for cancer treatment, is a T-type calcium channel blocker which arrests tumor cells at their most vulnerable metabolic point. TAU Therapeutics is developing Mibefradil. Scynexis and